Perspectives on Real-World Management of Stomatitis/Oral Mucositis (S/OM) From Oncologists With Experience Treating Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Metastatic Breast Cancer (mBC)
Author(s)
Marvin Nguyen, PharmD, MS1, Ruchit Shah, PhD1, Jon Apple, PharmD, MS2, William John, PhD3, Sarah Lucht, PhD3, Prathamesh Pathak, MS3, Bryce A. Van Doren, MPH, MPA, MA3, Monica Ahlquist, MSPH3, Jay Laney, RN3, Bruce Feinberg, DO3.
1Daiichi Sankyo, Basking Ridge, NJ, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3Cardinal Health, Dublin, OH, USA.
1Daiichi Sankyo, Basking Ridge, NJ, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3Cardinal Health, Dublin, OH, USA.
Presentation Documents
OBJECTIVES: S/OM is a common tolerability concern associated with treatment for mNSCLC and mBC. S/OM may be associated with pain, difficulty swallowing, and reduced patient quality of life. The goal of this research was to document oncologist awareness of S/OM guidelines, perceived risk factors for S/OM development, and barriers to S/OM care to improve management of S/OM.
METHODS: US oncologists from the Cardinal Health Oncology Provider Extended Network, who have experience managing antineoplastic therapy-induced S/OM in patients with mNSCLC and mBC, were surveyed. The survey collected data on demographics, awareness of S/OM management guidelines, and oncologists’ perceptions of risk factors and barriers to management.
RESULTS: The survey included 31 physicians with an average of 16 years in practice: 90% identified as medical oncologists,74% were from community practices, and 94% had experience in treating both mNSCLC and mBC. Only 39% of oncologists reported awareness of any published S/OM management strategies/guidelines. When asked about S/OM-dedicated training for their practice, most oncologists reported self-directed training (74%), with a portion reporting no training at all (10%). 13% of oncologists reported patient adherence, knowledge of and access to S/OM management guidelines, and physician or pharmacist reimbursement to be major barriers to S/OM management, while 10% reported lack of manufacturer guidance and access to dentists as major barriers. Patient- and treatment-related factors considered to be very high risk for developing S/OM include poor oral hygiene (55%), type of treatment (39%), treatment dose (29%), and smoking status (26%).
CONCLUSIONS: Despite the occurrence of S/OM in their patients, most oncologists lacked awareness of any published S/OM management guidelines. In combination with key barriers to S/OM management, an unmet need exists to improve oncologist awareness of and access to educational resources to help oncologists overcome management barriers and enhance care for S/OM.
METHODS: US oncologists from the Cardinal Health Oncology Provider Extended Network, who have experience managing antineoplastic therapy-induced S/OM in patients with mNSCLC and mBC, were surveyed. The survey collected data on demographics, awareness of S/OM management guidelines, and oncologists’ perceptions of risk factors and barriers to management.
RESULTS: The survey included 31 physicians with an average of 16 years in practice: 90% identified as medical oncologists,74% were from community practices, and 94% had experience in treating both mNSCLC and mBC. Only 39% of oncologists reported awareness of any published S/OM management strategies/guidelines. When asked about S/OM-dedicated training for their practice, most oncologists reported self-directed training (74%), with a portion reporting no training at all (10%). 13% of oncologists reported patient adherence, knowledge of and access to S/OM management guidelines, and physician or pharmacist reimbursement to be major barriers to S/OM management, while 10% reported lack of manufacturer guidance and access to dentists as major barriers. Patient- and treatment-related factors considered to be very high risk for developing S/OM include poor oral hygiene (55%), type of treatment (39%), treatment dose (29%), and smoking status (26%).
CONCLUSIONS: Despite the occurrence of S/OM in their patients, most oncologists lacked awareness of any published S/OM management guidelines. In combination with key barriers to S/OM management, an unmet need exists to improve oncologist awareness of and access to educational resources to help oncologists overcome management barriers and enhance care for S/OM.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HSD63
Topic
Health Service Delivery & Process of Care
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology